Articles related to TARGETED THERAPIES

As we navigate this new era of oncology care, it’s important to remember that only 38% of studies combining chemotherapy with a targeted treatment administered both drugs at full dose. This underscores the need for careful dose adjustments when combining different classes of drugs.

As we embrace the era of antibody-drug conjugates (ADCs) in cancer therapy, it’s crucial to understand their impact on ocular health. With ADCs like mirvetuximab offering new hope for ovarian cancer patients, effective partnerships between optometrists and oncologists are key to managing associated ocular adverse events.

Discover how mechanoresilient cancer cells evade the body’s natural defenses and what this means for the future of targeted cancer therapies.

Understanding the ocular side effects of targeted cancer therapies is crucial. Early monitoring and interdisciplinary communication can significantly impact treatment outcomes.

Explore the intricacies of diagnosing and treating acral melanoma, a subtype that presents unique challenges but also offers new avenues for targeted therapies and immune modulation.

The FDA’s recent approval of Akeega, a combination therapy for BRCA-mutated mCRPC, marks a significant advancement in targeted treatment. This approval, based on the MAGNITUDE study, offers a new therapeutic option for patients, supported by robust clinical data.